P21

Summary

P21 (P021) is a CNTF-mimetic peptide (Ac-DGGL(A)G-NH2) that pairs a 4-residue fragment of ciliary neurotrophic factor with an adamantane-cage glycine for stability and brain penetration. In transgenic Alzheimer mice, chronic oral treatment increased dentate gyrus neurogenesis, reduced tau hyperphosphorylation, and rescued cognition. It has never been given to humans in a published study, and all in vivo work comes from a single research group.

Also known as: P021, P-21, Peptide 021, Ac-DGGL(A)G-NH2

Cognitive Enhancement C27H42N6O8

Key Findings at a Glance

  • • P021 is a rationally designed CNTF mimetic: the CNTF(148-151) fragment DGGL with N-acetyl and a C-terminal adamantane-cage glycine amide, giving oral, brain-penetrant activity.
  • • Chronic oral treatment of 3xTg-AD mice reduced tau hyperphosphorylation via the BDNF/TrkB/GSK3-beta axis and rescued cognition, neurogenesis, and synaptic plasticity; a prevention-start design also markedly reduced mortality.
  • • In aged rats it normalized elevated CSF tau to young-adult levels without a detectable immune reaction, a notable tolerability signal for a peptide.
  • • The entire evidence base is one research group's mouse and rat work; there is no human study and no independent replication, which caps confidence in the headline claims.
Research Disclaimer: Information provided is for educational purposes only. This peptide is intended for laboratory research use only and is not approved for human use. Consult qualified professionals before conducting research.

P21 Overview & Molecular Profile

P21 (P021) is a synthetic neurotrophic peptide mimetic designed by the Iqbal and Grundke-Iqbal group at the New York State Institute for Basic Research in Developmental Disabilities. It consists of an N-acetylated tetrapeptide (Asp-Gly-Gly-Leu) corresponding to a biologically active region of human ciliary neurotrophic factor (CNTF residues 148-151), C-terminally fused to an adamantane-cage glycine mimetic amide that increases stability and lipophilicity; the primary literature writes it as Ac-DGGL(A)G-NH2 (PubChem CID 56599151; C27H42N6O8; CAS 1246751-68-7). The design goal was explicit: a small, blood-brain-barrier-permeable compound that mimics the neurogenesis-promoting action of CNTF without CNTF's size, instability, and inflammatory liabilities. The 2010 FEBS Letters discovery study showed peripheral administration improved learning and memory and boosted dentate gyrus neurogenesis in normal adult mice. Follow-up work in 3xTg-AD Alzheimer mice reported disease-modifying effects after chronic oral dosing: reduced tau hyperphosphorylation, rescued neurogenesis and synaptic plasticity deficits, improved cognition, and, in a prevention design, reduced mortality. Aged-rat cerebrospinal fluid studies showed reduced tau levels and no detectable immune reaction. All published in vivo evidence comes from the same research group, and no human study of any kind has been published.

Mechanism of Action: Neuroprotection & Synaptic Plasticity

P021 acts as a neurotrophic factor mimetic rather than through a single defined receptor. In 3xTg-AD mice it increased hippocampal BDNF expression, engaging the BDNF/TrkB/PI3K/AKT axis and inhibiting glycogen synthase kinase-3-beta (GSK3-beta), the principal tau kinase; this provides a mechanistic link to the observed reduction in abnormal tau hyperphosphorylation (PMID: 25046994). In the dentate gyrus it enhanced neurogenesis and the maturation of newly born neurons in the granular cell layer and subgranular zone, coupling neurogenesis to improved synaptic plasticity measures (PMID: 20600002). The compound is blood-brain-barrier permeable after oral dosing, attributed to the adamantane cage and end caps, and reduced brain total tau and CSF tau toward young-adult levels in aged rats (PMID: 26401692). Amyloid effects are limited: soluble A-beta levels fell in 3xTg-AD mice but plaque load only trended down, consistent with reduced A-beta generation rather than clearance.

Research-Observed Effects

Adult Hippocampal Neurogenesis

Moderate Research

The discovery study showed that peripherally administered P021 increased neurogenesis and maturation of newborn neurons in the granular cell layer and subgranular zone of the dentate gyrus in normal adult C57Bl6 mice, alongside improved learning, short-term, and spatial reference memory (PMID: 20600002). Neurogenesis rescue was later replicated in 3xTg-AD mice, where the compound restored deficits rather than augmenting baseline. This is the defining and best-documented effect of the peptide, though all demonstrations come from one research group.

Tau Pathology Reduction

Moderate Research

Chronic oral P021 significantly reduced abnormal hyperphosphorylation and accumulation of tau at major Alzheimer neurofibrillary-pathology sites in 3xTg-AD mice, mechanistically tied to BDNF-mediated inhibition of GSK3-beta (PMID: 25046994). In aged Fisher rats, chronic treatment reduced brain total tau and brought elevated CSF tau down to young-adult levels (PMID: 26401692). Two convergent models support the tau effect; no human biomarker data exists.

Cognitive Rescue in Alzheimer Models

Moderate Research

In 3xTg-AD mice treated for 12 months from 9-10 months of age, P021 rescued deficits in cognition, neurogenesis, and synaptic plasticity at both moderate and severe pathology stages (PMID: 25046994). A prevention study starting treatment at 3 months, before overt pathology, prevented neurodegeneration, A-beta and tau pathologies, episodic memory impairment, and markedly reduced mortality (PMID: 28387677). Treatment initiated during early postnatal development likewise prevented Alzheimer-like behavior and synaptic dysfunction (PMID: 34057082).

Synaptic Plasticity Enhancement

Moderate Research

Beyond neuron birth, the discovery study reported improved synaptic plasticity alongside the memory gains, and chronic oral treatment later rescued synaptic plasticity deficits in 3xTg-AD mice together with cognition and neurogenesis (PMID: 20600002, 25046994). The coupling of neurogenesis with synaptic recovery is the basis for the group's neurotrophic-compound therapeutic framework.

Amyloid-Beta Effects

Preliminary Research

The amyloid dimension is deliberately modest: in 3xTg-AD mice, P021 significantly decreased soluble A-beta levels but produced only a trend toward reduced CA1 plaque load, a pattern the authors interpreted as reduced A-beta generation rather than plaque clearance (PMID: 25046994). Claims of anti-amyloid action beyond this are not supported by the published data.

Safety & Tolerability

P021 has no human safety data of any kind; it has been studied only in rodents. Within that limit, the published record is favorable: chronic oral administration for up to 12-18 months was tolerated in transgenic mice, and an aged-rat study explicitly found no detectable immune reaction. The concentration of all evidence in a single research group, with no independent replication, is itself a safety-relevant caveat.

Human data: No human trials, human pharmacokinetics, or human exposure data exist. The compound has been administered only to mice and rats in published research.

Regulatory status: Not approved anywhere; a preclinical research compound with no registered clinical trial.

  • Twelve months of chronic oral P021 in 3xTg-AD mice produced disease-modifying effects without reported toxicity, and the prevention-start study additionally reported markedly reduced mortality in treated animals.

    Animal
    PubMed 25046994

  • In aged rats, chronic oral P021 reduced elevated CSF tau to young-adult levels and, notably for a peptide drug candidate, did not induce any detectable immune reaction.

    Animal
    PubMed 26401692

  • Treatment from birth to postnatal day 120 in 3xTg-AD mice prevented Alzheimer-like behavior and synaptic dysfunction; developmental-stage exposure showed no reported adverse effect in that study.

    Animal
    PubMed 34057082

  • All published P021 in vivo work originates from a single research group (Iqbal/Grundke-Iqbal, NYS Institute for Basic Research); independent replication has not been published, and vendor dosing schedules have no pharmacokinetic basis.

    Theoretical

Research Protocol Doses Reported in Published Literature

Research Disclaimer: Doses reported below are from published preclinical research protocols. P21 is not approved by the US FDA for human use; regulatory status can differ in other countries, so see the regulatory status note in the safety section of this page. This information is provided for research reference only and does not constitute a dosing recommendation.

Route Dose Frequency Notes
Oral, admixed in diet (mouse) 60 nmol/g of formulated diet Continuous, weeks to 12 months 3xTg-AD chronic treatment, prevention, and early-development studies (PMID: 25046994, 28387677, 34057082)
Intraperitoneal (mouse) Peripheral dosing over 4 weeks Per protocol Discovery study in normal adult C57Bl6 mice (PMID: 20600002)

All doses above are reported from published research protocols using laboratory subjects. Refer to the cited studies in the Research Studies section above for original source data.

Research Studies & References

Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice

Li B, Wanka L, Blanchard J, et al.

FEBS Letters (2010)

The discovery paper: the Iqbal group designed P21 (Ac-DGGLAG-NH2), a CNTF-derived peptide incorporating an adamantane-containing glycine mimetic, to mimic neurotrophin action while surviving peripheral administration. Given peripherally to normal adult C57Bl6 mice, P21 enhanced learning, short-term and spatial reference memory, induced neurogenesis and maturation of newborn neurons in the dentate gyrus granular layer and subgranular zone, and increased synaptic markers. It established both the compound and the adamantane-stabilization design principle.

PubMed DOI

Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease

Kazim SF, Blanchard J, Dai CL, et al.

Neurobiology of Disease (2014)

The flagship efficacy study: 3xTg-AD and wild-type female mice received P021 (Ac-DGGL(A)G-NH2) or vehicle diet for 12 months starting at 9-10 months of age, covering moderate to severe pathology stages. Treatment significantly reduced abnormal tau hyperphosphorylation and accumulation at major neurofibrillary sites, decreased soluble A-beta (with only a trend on plaques, implying reduced generation rather than clearance), and rescued cognition, neurogenesis, and synaptic plasticity deficits. The mechanism was traced to increased BDNF expression with downstream inhibition of GSK3-beta activity.

PubMed DOI

Elevated Tau Level in Aged Rat Cerebrospinal Fluid Reduced by Treatment with a Neurotrophic Compound

Khatoon S, Chalbot S, Bolognin S, et al.

Journal of Alzheimer's Disease (2015)

This aged-Fisher-rat study produced three notable findings: P021 is blood-brain-barrier permeable; chronic oral treatment reduced brain total tau and brought the age-elevated CSF tau level down to that of young adult rats (CSF A-beta/A-betaPP, also elevated with age, was not reduced); and P021 induced no detectable immune reaction, an important early tolerability signal for a peptide therapeutic. The CSF tau finding frames a translational biomarker strategy the authors proposed for future trials.

PubMed DOI

Prevention of Amyloid-beta and Tau Pathologies, Associated Neurodegeneration, and Cognitive Deficit by Early Treatment with a Neurotrophic Compound

Baazaoui N, Iqbal K

Journal of Alzheimer's Disease (2017)

A secondary-prevention experiment: continuous P021 treatment of 3xTg-AD mice was started at 3 months of age, during the synaptic compensation period months before overt pathology. Followed at 9, 15, and 18 months of treatment, treated animals showed prevention of neurodegeneration (Fluorojade C), of A-beta and tau pathologies (immunohistochemistry and Western blot), and of episodic memory impairment (novel object recognition at 16-17 months), plus a marked reduction in mortality rate. It is the strongest claim in the P021 literature and awaits independent replication.

PubMed DOI

Neurotrophic Treatment Initiated During Early Postnatal Development Prevents the Alzheimer-Like Behavior and Synaptic Dysfunction

Wei W, Liu Y, Dai CL, et al.

Journal of Alzheimer's Disease (2021)

Extending the prevention paradigm to its limit, this study treated 3xTg-AD and wild-type female mice with P021 in diet (60 nmol/g formulated diet) from birth to postnatal day 120. Early-development treatment prevented the emergence of Alzheimer-like cognitive deficits and synaptic dysfunction. The paper also documents the compound's identity precisely: Ac-DGGL(A)G-NH2, monoisotopic molecular weight 578.3 (average 578.7), corresponding to human CNTF residues 148-151 with C-terminal adamantylated glycine added to increase stability and lipophilicity.

PubMed DOI

Frequently Asked Questions

What is P21 and how is it related to CNTF?

P21 (P021) is a synthetic mimetic of ciliary neurotrophic factor. It takes a 4-amino-acid active-region fragment of human CNTF (residues 148-151, Asp-Gly-Gly-Leu) and adds an N-terminal acetyl group and a C-terminal adamantane-cage glycine mimetic amide, written Ac-DGGL(A)G-NH2. The goal was to keep CNTF's neurogenesis-promoting activity in a small, stable, brain-penetrant compound, avoiding full-length CNTF's delivery and inflammatory problems.

Has P21 been tested in humans?

No. Every published P021 study is preclinical, conducted in mice or rats, and all in vivo work comes from a single research group (the Iqbal group at the NYS Institute for Basic Research). There is no human pharmacokinetic, safety, or efficacy data, no registered clinical trial, and no independent replication of the headline Alzheimer-mouse findings.

What did the Alzheimer mouse studies actually show?

In 3xTg-AD mice, 12 months of oral P021 from 9-10 months of age reduced tau hyperphosphorylation and soluble amyloid, rescued cognition, neurogenesis, and synaptic plasticity (PMID: 25046994). Started at 3 months before pathology appeared, it prevented neurodegeneration, both pathologies, and memory impairment, and markedly reduced mortality (PMID: 28387677). Mechanistically, the effect ran through increased BDNF and inhibition of the tau kinase GSK3-beta.

What is the adamantane group for?

Adamantane is a rigid lipophilic hydrocarbon cage. Fusing it to the peptide's C-terminus (as an adamantane-glycine mimetic) increases resistance to proteolytic degradation and raises lipophilicity, which the design study credits for the compound's oral activity and blood-brain barrier permeability. The same stabilization idea is used, without published validation, in vendor peptides like Adamax.

Does P21 clear amyloid plaques?

No, and the primary data says so plainly. In 3xTg-AD mice, P021 significantly lowered soluble A-beta levels but produced only a nonsignificant trend toward reduced CA1 plaque load, which the authors interpreted as reduced A-beta generation rather than plaque clearance (PMID: 25046994). Its pathology effect is predominantly on tau, neurogenesis, and synaptic plasticity.

Related Peptides

View all

Adamax

Adamax is an unofficial, vendor-market derivative of the Russian nootropic peptide Semax with N-terminal acetylation and a C-terminal adamantane group. No peer-reviewed study of Adamax itself has been published.

Dihexa

Dihexa is a synthetic peptide derivative of angiotensin IV that has been studied for potent nootropic and neuroprotective effects. It is reported to be extremely potent in promoting cognitive function.

Cerebrolysin

Cerebrolysin is a neuropeptide preparation derived from purified porcine brain proteins, consisting of low-molecular-weight peptides and free amino acids that mimic the action of endogenous neurotrophic factors.

Omberacetam

Omberacetam (Noopept, GVS-111) is a Russian-developed dipeptide mimetic of piracetam with nootropic and neuroprotective properties, studied in one comparative human trial and an extensive preclinical program.

Semax

Semax is a synthetic peptide derived from adrenocorticotropic hormone (ACTH). It was developed in Russia as a nootropic and neuroprotective agent with applications in cognitive enhancement research.

Follow Peptpedia on Google

Add Peptpedia as a Preferred Source and Google can highlight our links with a "preferred" badge in your Top Stories and AI Overviews.